# Do GLP-1 Drugs Cause Acid Reflux? Three Databases Say More Reports | This GLP Do GLP-1 drugs cause acid reflux? Reporting ratios of 2.83, 2.91 and 4.76 across three national databases, gastric ultrasound in 124 fasted patients, and what a reporting ratio cannot tell you. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Acid Reflux? Three Databases Say More Reports Reporting ratios of 2.83, 2.91 and 4.76 across three countries. Exenatide, in the same class, ran inverse at 0.60. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Reflux reporting ratio, vs DPP-4 drugs · FAERS (US) · 9,245 vs 139 · 2.83 · Canada Vigilance · 206 vs 29 · 2.91 · JADER (Japan) · 19 vs 16 · 4.76 · The largest ratio rests on the fewest reports. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Reflux is reported more often on a GLP-1 than on its closest drug comparator. Across 260,417 GLP-1 reports in three national databases, the reporting odds ratio was 2.83 in the United States [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-1). Canada Vigilance gave 2.91 and Japan’s JADER gave 4.76. None of those three numbers is a risk. A reporting ratio counts reports, not patients. Exenatide, in the same class, ran the other way at 0.60. The slowed stomach underneath all of it is set out in [the gastroparesis evidence](https://thisglp.com/research/do-glp1-drugs-cause-gastroparesis). ## Key takeaways - Across 260,417 GLP-1 reports in three national databases, reflux was reported disproportionately often against DPP-4 inhibitors as the comparator. - FAERS gave a reporting odds ratio of 2.83 (95% CI 2.39-3.35) from 9,245 reports against 139; Canada 2.91 from 206 against 29; Japan 4.76 from just 19 against 16. - Exenatide went the other way, at 0.60 (95% CI 0.46-0.77) — an inverse signal inside the same drug class. - A reporting odds ratio has no denominator of people taking the drug. It cannot tell you your chance of getting reflux. - Gastric ultrasound in 124 fasted patients found retained stomach contents in 56% against 19%, which is the mechanism reflux would run through. - Gastroparesis, the far end of the same mechanism, has thirteen published cases worldwide. ## What the three databases found One 2026 study ran the same analysis over the American, Japanese and Canadian adverse event databases [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-1). The comparator was DPP-4 inhibitors, not the whole database. All three sources produced a signal. FAERS gave 2.83 (95% CI 2.39–3.35). Canada Vigilance gave 2.91 (95% CI 1.97–4.31). Japan’s JADER gave 4.76 (95% CI 2.45–9.27). Semaglutide carried the strongest drug-specific signal in all three. The signal rose with age, reaching 3.01 at 65 and over. Age also tracks the rest of a person’s medication list, which [the frailty analysis](https://thisglp.com/research/frailty-did-not-change-the-answer) sets out. Read the counts, not the ratios The Japanese figure is the largest number in the study. It rests on 19 reports against 16. The American figure is less than half as large and rests on 9,245 against 139. A ratio built on a few dozen events is unstable. That is why the Japanese interval runs from 2.45 to 9.27 while the American one spans barely a point. ## The one drug that ran the other way Exenatide is an older drug in the same class. In FAERS it returned a reporting odds ratio of 0.60 (95% CI 0.46–0.77). That is fewer reflux reports than the comparator, not more. Disagreement inside one class is hard to explain by notoriety. Attention should lift a famous class together, not push one member below the line. The objection still holds for the rest of the class. Semaglutide is the most discussed medicine on the market. Attention drives reporting, and the drug with the most attention carries the strongest signal. This design cannot separate those two facts. Consistency across three countries does not fix it, because the same drug is famous in all three. ## The mechanism has been measured directly Reflux would run through delayed gastric emptying. That has a measurement of its own. Gastric ultrasound was performed on 124 patients who had followed standard fasting instructions [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-2). Retained stomach contents were found in 56% against 19% of the unexposed group. The adjusted prevalence ratio was 2.48 (95% CI 1.23 to 4.97). Stopping the drug earlier did not help: the adjusted odds ratio for interruption length was 0.86 (95% CI 0.65 to 1.14). The procedural consequence is in [what to tell the anesthesiologist](https://thisglp.com/research/glp1-before-surgery). ## Where the far end of it sits Gastroparesis is delayed emptying severe enough to carry a diagnosis. A systematic review searched four databases to October 2025 and found twelve case reports covering thirteen patients [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-acid-reflux#ref-3). Onset ran from hours to several months. It usually followed a dose increase or a restart after a gap. Stopping the drug resolved it in every reported patient. Thirteen cases is not a rate, because a case series has no denominator. ## What a reader can do with this Take direction, not magnitude. Reflux belongs on the list of plausible effects of this class. Belching is a separate label entry, covered in [why Ozempic causes sulfur burps](https://thisglp.com/research/why-does-ozempic-cause-sulfur-burps). Exenatide means it is not obviously a class effect. Nothing here states how likely it is for any one person. Trial-based figures carry denominators and are the place to look. The escalation pattern behind most stomach complaints is in [titration and nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). The wider safety picture is in [the cancer risk evidence](https://thisglp.com/research/do-glp1-drugs-cause-kidney-cancer). ## Frequently asked Do GLP-1 drugs cause acid reflux? Reflux is reported disproportionately often on them. Reporting odds ratios were 2.83 in the US database, 2.91 in Canada and 4.76 in Japan, against DPP-4 inhibitors as the comparator. Exenatide, in the same class, ran inverse at 0.60. How likely am I to get reflux on a GLP-1? This study cannot say. A reporting odds ratio compares how often a term appears among reports, with no count of how many people took the drug, so it produces no incidence or personal risk. Why did exenatide show the opposite result? It is unexplained, and it is the most interesting result in the paper. An inverse signal within the same drug class is difficult to attribute to reporting bias, which would tend to lift the whole class together. Is the Japanese figure the strongest evidence? It is the largest ratio and the weakest evidence. It rests on 19 reports against 16, which is why its confidence interval runs from 2.45 to 9.27. ## Sources 1. \[1\] Choi JG, Gong EJ, Bang CS, Lee JJ (2026). Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study Gut and Liver. [PMID 42682267](https://pubmed.ncbi.nlm.nih.gov/42682267/) 2. \[2\] Sen S, et al. (2024). Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia JAMA Surgery. [PMID 38446466](https://pubmed.ncbi.nlm.nih.gov/38446466/) 3. \[3\] Olubodun T, et al. (2026). Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes PLOS ONE. [PMID 42594084](https://pubmed.ncbi.nlm.nih.gov/42594084/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness)